Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
80 participants
INTERVENTIONAL
2025-12-31
2026-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Does adding the SleepQ app to care as usual (CAU) improve insomnia symptoms after 12 weeks?
* Does SleepQ also improve depressive symptoms, anxiety, beliefs about sleep and daily functioning?
Researchers will compare CAU + SleepQ to CAU alone to see whether SleepQ provides additional benefits for sleep and well-being.
Participants will take part remotely from home, be randomly assigned to either SleepQ+CAU or CAU alone, and complete online questionnaires at baseline, week 6, and week 12 about their sleep, mood, and daily functioning.
Participants in the intervention group will use the SleepQ app for 12 weeks while continuing their usual care.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The pilot clinical trial will evaluate the effectiveness of SleepQ as an add-on to care as usual (CAU) compared with CAU alone in adults diagnosed with insomnia. Approximately 80 adult participants with a confirmed diagnosis of insomnia will be enrolled and randomized in a 1:1 ratio to the intervention group (SleepQ + CAU) or the control group (CAU alone). The study will be conducted as a fully decentralized trial within Germany. Screening, informed consent, eligibility confirmation, randomization, and all outcome assessments will be conducted remotely. Participants will complete self-reported questionnaires at baseline, week 6, and week 12 to assess changes in insomnia severity and related symptoms.
The primary endpoint is the reduction in insomnia symptoms after 12 weeks, and secondary outcomes include changes in depressiv symptoms, anxiety, dysfunctional beliefs about sleep, and daily functioning.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SleepQ Digital Cognitive Behavioral Therapy for Insomnia (dCBT-I)
SleepQ Digital Cognitive Behavioral Therapy for Insomnia (dCBT-I)
SleepQ is a fully digital, individualized 12-week cognitive behavioral therapy program for adults with insomnia. The intervention is delivered via the SleepQ mobile application and includes structured CBT-I components such as sleep restriction therapy, stimulus control, psychoeducation, cognitive restructuring, sleep hygiene training, and daily sleep diary input, in addition to Care-as-Usual (CAU).
Care-as-Usual (CAU)
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SleepQ Digital Cognitive Behavioral Therapy for Insomnia (dCBT-I)
SleepQ is a fully digital, individualized 12-week cognitive behavioral therapy program for adults with insomnia. The intervention is delivered via the SleepQ mobile application and includes structured CBT-I components such as sleep restriction therapy, stimulus control, psychoeducation, cognitive restructuring, sleep hygiene training, and daily sleep diary input, in addition to Care-as-Usual (CAU).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Confirmed current diagnosis of F51.0 Nonorganic insomnia or G47.0 Sleep disorders
* Possession of a mobile device with internet connection (must be run on iOS software, minimum version 18) with internet connection
* Sufficient German language proficiency required for the correct use of the intervention and the mobile device
* Personal e-mail address for registration
* Willing and able to provide written informed consent
* Insomnia Severity Index (ISI) socre of 15 or higher, indicating clinically relevant symptoms of insomnia
* Registered with a GP, sleep specialist or other health care professional
Exclusion Criteria
* PHQ-9 score at screening ≥ 20 and/or item 9 f PHQ-9 ≥ 1
* GAD-7 score at screening ≥ 15
* Intermittent use and/or recent initiation (\< 3m) or planned use of insomnia specific prescription-only pharmacological therapy
* Intermittent use and/or recent initiation (\< 3m) or planned use of a psychotropic during the study period which has recognised potential effects on insomnia
* Participation in CBT or other psychotherapy to treat sleep disorders in the last 6 months (outpatient, inpatient) or planned start during the study period
* Known history or diagnosis of substance or alchol abuse or dependence within 12 months prior to screening (diagnosis of F10-F19, excluding F17.1 and F17.2)
* Current or planned participation in other clinical trials during the study period
* Working in shifts
* Currently pregnant or planning to become pregnant within the next 3 months
* Any surgical procedure that was scheduled, planned, or conducted within the timeframe of the study (minor outpatient procedures under local anaesthetic or with no anesthetic are permitted)
* Diagnosis of epilepsy
* Presence of serious mental illness, such as (schizophrenia F 20.-, acute transient psychotic disorders F23.-, active manic episode F30.-, bipolar disorder F31.-, severe depression F32.3, F33.3)
* Other diseases (such as acute or severe cardiac diseases, acute or severe respiratory diseases, acute or severe gastrointestinal diseases), conditions or therapies which, in the opinion of the investigator, could confound the study results or contraindicate participation.
* Acute suicidal thoughts or intentions within the past 12 months
* Presence of obstructive sleep apnea, restless legs syndrome, parasomnia, and other sleep behavior problem
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
WELT corp
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Berlin Medical Association (Ärztekammer Berlin)
Berlin, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Ethics Committee of the Berlin Medical Association
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
WCTP-DI-A-01
Identifier Type: -
Identifier Source: org_study_id